Fulcrum Therapeutics Insider Grant: Zero‑Strike Option Fuels Long‑Term Value & Gene‑Regulation Progress
Director Joshua Lehrer‑Graiwer’s zero‑strike option grant at Fulcrum Therapeutics shows strong executive confidence, aligns incentives with a promising gene‑regulation pipeline, and signals potential upside for long‑term investors.
4 minutes to read